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Abstract
Background: Brazil was the first middle-income country to provide free and universal access to AIDS treatment.
Understanding the impact of this policy is key to promote ongoing improvement of current intervention strategies.
The aim of this study was to compare mortality rates and survival in a cohort of AIDS patients before and after the
introduction of antiretrovirals (ARV) and to investigate predictors of survival.
Methods: A retrospective cohort study of AIDS patients aged 13 years or more living in the city of Sao Paulo was
conducted. All patients were recruited from an STD/HIV outpatient clinic between 1988 and 2003 and followed up until
2005. We estimated AIDS mortality rates in person-years (py) and carried out a survival analysis using the Kaplan-Meier
method. The Cox proportional hazards model was used to assess predictors of survival in AIDS patients.
Results: The study cohort comprised 6,594 patients. The yearly mean mortality rates were 17.6, 23.2, and 7.8 per 1,000
py for the study periods 1988–1993, 1994–1996, and 1997–2003, respectively. Median survival time was 13.4 and
22.3 months for patients entering the study in the first and second study periods and survival time was 108 months or
more in 72% of those entering the study during 1997–2003. Factors independently associated with shorter survival
included: AIDS diagnosis during the 1994–1996 (HR 2.0) and 1988–1993 (HR 3.2) periods; 50 years of age or more (HR
2.0); exposure category of injection drug users (IDU) (HR 1.5); 8 years of schooling or less (HR 1.4); no schooling (HR 2.1);
and CD4+ counts between 350 and 500 cells/mm3 (HR 1.2) and less than 350 cells/mm3 at AIDS diagnosis (HR 1.3).
Conclusions: The study showed a strong impact following the introduction of HAART in 1996 with decreased AIDS
mortality, increased survival rates, and benefits with early introduction of HAART. However, some groups of patients
were less likely to benefit from the new drug regimens. Public policies promoting health equity create an enabling
environment helping AIDS control programs in developing countries to achieve their goals as effectively as in
developed countries.
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Background
The introduction of highly active antiretroviral therapy
(HAART) has dramatically changed the course of the
HIV/AIDS epidemic. It has decreased AIDS mortality
rates and both increased survival and improved quality of
life of people living with HIV/AIDS [1]. Understanding
the impact of HAART on the survival of AIDS patients
and its predictors is key to promote ongoing improvement
of current intervention strategies [2].
Brazil was the first middle-income country to provide
in 1996 free and universal access to HAART for AIDS
treatment [3]. This policy resulted in increased survival of
people living with AIDS, from an estimated five months
during the period 1982–1989 [4] to 58 months among
new cases diagnosed in 1996 [5]. A recent study of new
cases diagnosed in South and Southeast Brazil during the
period 1998–1999 showed a survival time of at least
108 months in 50% of patients after diagnosis [6].
There is a need to better understanding the impact of
the Brazilian policy of universal access to AIDS treatment
as many other developing countries have implemented
similar guidelines in recent years. However, most studies
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in Brazil have focused their analyses on the first years fol-
lowing the introduction of HAART [5,7].
The aim of this study was to compare mortality rates
and survival of AIDS patients before and after the intro-
duction of antiretrovirals (ARV) and to investigate pre-
dictors of survival in a cohort of AIDS patients living in
the city of Sao Paulo who were diagnosed between 1988
and 2003 and followed as of the end of 2005.
Methods
A retrospective cohort study of people living with AIDS
in the city of Sao Paulo, southeastern Brazil, was con-
ducted. Brazil’s largest metropolitan area with a popula-
tion of around 11 million, the city of Sao Paulo has been
hit hard by the HIV/AIDS epidemic accounting for
about 15% of all cases reported in the country [8].
All patients recruited to the study attended the STD/
AIDS Referral and Training Center (CRT-DST/AIDS)
outpatient clinic. The study cohort comprised AIDS pa-
tients aged 13 years old or more living in the city of Sao
Paulo with AIDS diagnosis confirmed between January 1st,
1988 and December 31, 2003 and followed up until
December 31, 2005 (Figure 1). The CRT-DST/AIDS clinic
is one of the three specialized centers in Sao Paulo that
provide outpatient care to individuals with HIV/AIDS.
The AIDS case definition was any HIV-infected individ-
ual with at least one AIDS-defining illness and/or CD4+
counts below 350 cells/mm3 regardless of other existing
causes of immunodeficiency.
The AIDS case definition for adults changed over the
study period following the Brazilian Ministry of Health
recommendations: 1) CDC criteria; 2) Rio de Janeiro/
Caracas criteria; 3) death exceptional criterion; and 4)
adapted CDC criteria. Because there was insufficient infor-
mation available to apply for all cases the latest AIDS case
definition, we chose to use the case definition that was in
effect in each period studied [9]. The exposure categories
for HIV transmission and treatment regimens were defined
according to the Brazilian Ministry of Health criteria [10].
We considered the date of inclusion in the study as
the date of confirmation of AIDS diagnosis. Only outpa-
tients enrolled in the CRT-DST/AIDS clinic were in-
cluded in the study. There were excluded: 1) individuals
infected through mother-to-child transmission or blood
transfusion; 2) those who died within thirty days after
AIDS diagnosis; and 3) those attending a single visit only
or followed up for less than 30 days.
The study variables included sociodemographic and be-
havior characteristics; characteristics related to diagnosis
(CD4+ count at AIDS diagnosis) and treatment regimen;
and time from AIDS diagnosis to AIDS-related death.
Data was obtained from the following sources of infor-
mation: CRT-DST/AIDS database (medical and surveil-
lance records); Integrated São Paulo AIDS Database
(BIPAIDS) which is a linkage database created from the
Figure 1 Study design flow chart for AIDS cohort study. AIDS Cohort, CRT-DST/AIDS, 1988–2003.
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State Data System Foundation (SEADE) death database
and the São Paulo AIDS Program (PEDST-AIDS) Noti-
fiable Diseases Database (SINAN-AIDS) [11]; and the
databases of the Brazilian Ministry of Health Laboratory
Tests System Control (SISCEL) and Drug Logistics
System Control (SICLOM).
The initial cohort included 15,663 individuals enrolled
as CRT-DST/AIDS outpatients between January 1st,
1988 and December 31, 2003. This database was linked
to BIPAIDS, SISCEL and SICLOM databases. Of these,
there were excluded 4,398 (28.1%) patients with negative
confirmatory HIV tests; 996 (6.3%) who were HIV-
infected, but AIDS-free; 634 (4.0%) who were not
diagnosed within the study period; 2,814 (18.0%) who
attended a single visit only or were followed up for less
than 30 days, 147 (0.9%) who were diagnosed with AIDS
at death; and 80 (0.5%) who were infected through verti-
cal transmission. The remaining 6,594/15,663 patients
(42.1%) were eligible to participate in the study.
Data analysis
A descriptive analysis of the main patient characteristics
was performed in the pre- (1988–1996) and post-HAART
periods (1997–2003).
We estimated AIDS mortality rates in person-years
(py). The numerator was the number of deaths and the
denominator was total person-years at risk of death (in
months). The denominator (person-years) was calculated
from the date of AIDS diagnosis to the date of AIDS-
related death or censoring date.
Data censoring occurred at three different situations:
1) at end of the study period on December 31, 2005 for
living patients at follow-up (administrative censoring);
2) at the date of death for those who died from a non-
AIDS-related cause; and 3) at the date of the last visit
for those lost to follow-up for one year.
We conducted an AIDS survival analysis using the
Kaplan-Meier method. Peto and log-rank tests were used
to compare time to the event (AIDS-related death)
among the groups.
AIDS survival time was estimated from the date of
AIDS diagnosis to the date of AIDS-related death or
censoring date (in months). Kaplan-Meier curves were
generated for the three AIDS diagnosis periods studied:
1988–1993, 1994–1996, and 1997–2003. Combination
ARV therapy and HAART became available in the last
two study periods, respectively. HAART became available
in 1996. These study periods were used as a proxy for dif-
ferent drug regimen exposures and measures of popula-
tional effectiveness of these interventions [2,12-14].
The Cox proportional hazards model was used to as-
sess factors associated with time from diagnosis of AIDS
to AIDS-related death and to estimate crude and ad-
justed hazard ratios (HR) with 95% confidence intervals
(95% CI). Variables that were statistically significant in
the bivariate analysis (p < 0.25) and biologically plausible
were included in the final Cox proportional hazards
model adjusted for treatment regimen. We used the like-
lihood ratio test to evaluate model fit. Schoenfeld resid-
uals were used to test the proportional risk assumption.
This study was approved by the University of São
Paulo School of Public Health research ethics committee
(protocol number 1612) and the CRT-DST/AIDS research
ethics committee (protocol number 211/06).
Results
The follow-up of the 6,594 patients with AIDS studied is
shown schematically in Figure 1. It shows their distribu-
tion according to exposure to different drug regimens
and whether or not they died from AIDS-related causes.
A comparison of patient characteristics in the pre-
(1988–1996) and post-HAART periods (1997–2003)
showed that 52% entered the study in the pre-HAART
period.
Compared with pre-HAART, there was in the post-
HAART period a lower proportion of injecting drug
users (IDU) (13% vs. 28%; p < 0.001) and a greater pro-
portion of heterosexuals (45% vs. 28%, p < 0.001), which
can be explained by an increase in the number of non-
IDU women infected, and patients with more than eight
years of schooling (61% vs. 46%, p < 0.001).
There were no statistically significant differences in
CD4+ counts at diagnosis between the first (median 251;
first quartile 119 and third quartile 405) and the second
period studied (median 220; first quartile 83 and third
quartile 363) (p = 0.283). Similarly, there was no signifi-
cant difference in viral load at AIDS diagnosis between
these two periods, ranging from 400 to 100,000 copies/
mL in 75% of the patients (p = 0.054). However, it should
be noted that only 546/3,464 (15.8%) patients had their
viral load measured in the first period.
Of the 6,594 patients studied, 2,936 (44.5%) died during
follow-up. From 1988 to 1993, there were 1,552 deaths
with a yearly mean mortality rate of 17.6 per 1,000 py.
During 1994–1996, there were 731 deaths with a yearly
mean mortality rate of 23.2 per 1,000 py, i.e., a 31.8% in-
crease. From 1997 to 2003, there were 653 deaths with a
yearly mean mortality rate of 7.8 per 1,000 py, a 66.4% de-
cline in AIDS mortality rate compared to the previous
period (Figure 2). Of all patients followed up, 3,698/6,594
(56.1%) were on treatment. Of them, 6.7% received mono-
therapy, 37.7% combination therapy and 55.6% HAART.
Figure 2 shows AIDS mortality rates year by year and the
proportion of drug regimen exposure.
The cumulative probability of survival over a maximum
follow-up time of 108 months (9 years) was 10.6% and
median survival time (MST) was 13.4 months (1.1 years)
among patients diagnosed with AIDS from 1988 to 1993.
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Among those diagnosed from 1994 to 1996, the cumulative
probability of survival was 24.4% and MST was 22.3 months
(1.8 years). In the last period studied (1997–2003), the cu-
mulative probability of survival over a maximum follow-up
time of 108 months was 72.0%. Over 50% patients were
alive at the end of the follow-up.
Figure 3 shows the analysis using Kaplan-Meier curves
for the three periods studied (1988–1993, 1994–1996,
1997–2003) which are consistent with the availability of
three different drug regimens. Survival increased among
those diagnosed with AIDS in the post-HAART period
(1997–2003) compared to the other periods studied
(log-rank =2,257.9, p < 0.001).
Figure 4 shows increased survival with the use of ARV
according to all variables analyzed, with a more pro-
nounced increase among those on HAART.
The Kaplan-Meier survival curve analysis for the post-
HAART period showed a decrease in survival with in-
creasing age (log-rank test for trend, p < 0.001); greater
survival rates in heterosexuals followed by MSM and
IDU (log-rank test, p < 0.001); and increase in survival
rates with increasing schooling (log-rank test for trend
p < 0.001) and CD4+ count at AIDS diagnosis (log-rank
test, p < 0.001) (Figure 4).
As for predictors of survival, the bivariate analysis
showed the following variables associated with shorter
Figure 2 AIDS mortality rates and proportion of drug regimens prescribed by year of AIDS diagnosis. AIDS Cohort, CRT-DST/AIDS, 1988–2003.
Figure 3 Cumulative probability of survival in patients diagnosed with AIDS, by study periods. AIDS-Cohort, CRT-DST/AIDS, 1988–2003.
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survival (time from AIDS diagnosis to death): AIDS diag-
nosed from 1994 to 1996 (HR 2.4, 95% CI: 2.2–2.7), and
from 1988 to 1993 (HR 6.9, 95% CI: 6.3–7.5); male sex
(HR 1.6, 95 % CI: 1.4–1.8); 50 years of age or more (HR
1.4, 95% CI: 1.2–1.6), white skin color (HR 1.6, 95% CI:
1.5–1.8); MSM (HR 1.5, 95% CI: 1.3–1.6) and IDU (HR
2.6, 95% CI: 2.4–2.9); 8 years of schooling or less (HR 2.0,
95% CI: 1.8–2.1); no schooling (HR 2.8, 95% CI: 2.1–3.7);
and CD4+ count at AIDS diagnosis between 350 and 500
cells/mm3 (HR 1.4, 95% CI: 1.0–1.9) and below 350 cells/
mm3 (HR 2.5, 95% CI: 1.9–3.2) (Table 1).
In the final model, shorter survival was independ-
ently associated with the following variables, regard-
less of other exposures: AIDS diagnosed from 1994
to1996 (HR 2.0, 95% CI: 1.8–2.2) and from 1988 to
1993 (HR 3.2, 95% CI: 2.8–3.5); 30–49 years of age
(HR 1.4, 95% CI: 1.2–1.5); 50 years of age or more
(HR 2.0, 95% CI: 1.7–2.3 ); MSM (HR 1.1, 95% CI:
1.1–1.2) and IDU (HR 1.5, 95% CI: 1.3–1.6); 8 years of
schooling or less (HR 1.4, 95% CI: 1.3–1.5); no school-
ing (HR 2.1, 95% CI: 1.6–2.8); and CD4+ count at
AIDS diagnosis between 350 and 500 cells/mm3 (HR
Figure 4 Cumulative probability of survival in patients with AIDS for the three study periods* according to age, exposure category,
schooling and CD4+ count at AIDS diagnosis**. AIDS Cohort, CRT-DST/AIDS, 1988–2003. *AIDS diagnosis periods (A) = the period from 1988
to 1993, (B) =1994-1996; (C) =1997-2003. **Log rank tests performed for each variable second periods of diagnosis.
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1.2, 95% CI: 1.1–1.2) and below 350 cells/mm3 (HR
1.3, 95% CI: 1.2–1.3) (Table 1).
Discussion
This is one of the few studies examining survival of AIDS
patients in Brazil in the pre- and post-HAART eras, most
likely the latest available data [4-7,15]. The study results
highlight the profound impact of the introduction of
HAART on the cohort of AIDS patients studied with a sig-
nificant decrease in mortality rates and increase in survival.
The study cohort accounted for 11.3% (6,594/58,185) of all
AIDS cases reported in the city of Sao Paulo during the
period studied [16]. Although the sample studied was not
representative, our results corroborate those reported by
the STD/AIDS Program in Sao Paulo showing a decline in
the mortality rate by 68% in the post-HAART period and a
2.8-fold increase in AIDS prevalence resulting from in-
creased survival, despite a 65% decline in new cases [16].
The AIDS epidemic in Sao Paulo has taken a favorable
course similar to that seen in developed countries [17,18].
It reflects the policies implemented in Brazil since 1996
providing free and universal access to HIV/AIDS treat-
ment [7,15,19]. As a result, the quality of life of people liv-
ing with HIV/AIDS has improved and opportunistic
infections and hospitalizations have been significantly
reduced [20].
In addition to a sharp decline in AIDS mortality and a
significant increase in survival time, a key finding of this
study is the fact that not all patients benefited equally
from new drug regimens and these benefits varied ac-
cording to individual characteristics of AIDS patients.
These differences, however, tended to be less remarkable
after the introduction of HAART. The study found that
shorter survival time was associated with being diagnosed
with AIDS in the pre-HAART period (as discussed be-
fore), more advanced age, exposure category of IDU, low
Table 1 Bivariate analysis and final Cox proportional hazards model for predictors of survival in AIDS patients
Characteristics AIDS Deaths
(n = 6,594) (n = 2,936) Crude HR 95% CI p-value Adjusted HR 95% CI p-value
Study period < 0.001 < 0.001
1997–2003 3130 653 1 - 1 -
1994–1996 1501 731 2.4 2.2–2.7 2.0 1.8–2.2
1988–1993 1963 1552 6.9 6.3–7.5 3.2 2.8–3.5
Gender < 0.001
Female 1526 517 1 - - -
Male 5068 2419 1.6 1.4–1.8 - -
Age(&) < 0.001 0.002
13–29 2099 953 1 - 1 -
30–49 4126 1784 1.0 0.9–1.1 1.4 1.2-1.5
50 or more 369 199 1.4 1.2–1.6 2.0 1.7–2.3
Race/skin color < 0.001
Black/brown 1348 452 1 - - -
White 5157 2456 1.6 1.5–1.8 - -
Exposure category(&) < 0.001 < 0.001
Heterosexuals 2310 735 1 - 1 -
MSM 2698 1215 1.5 1.3–1.6 1.1 1.1–1.2
IDU 1347 826 2.6 2.4–2.9 1.5 1.3–1.6
Schooling(&) < 0.001 0.0004
>8 years 3316 1119 1 - 1 -
8 years or less 2779 1514 2.0 1.8–2.1 1.4 1.3–1.5
None 78 48 2.8 2.1–3.7 2.1 1.6–2.8
CD4+ count(#) < 0.001 < 0.001
>500 cells/mm3 565 56 1 - 1 -
350–500cells/mm3 567 81 1.4 1.0–1.9 1.2 1.1–1.2
<350 cells/mm3 3040 733 2.5 1.9–3.2 1.3 1.2–1.3
HR: hazard ratio; Crude HR: crude hazard ratio; adjusted HR: adjusted hazard ratio.
(#)CD4+ count at AIDS diagnosis; (&) Baseline data.
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schooling and lower CD4+ counts at AIDS diagnosis
(a proxy measure for late diagnosis).
The inverse association between age and survival time
found in this study is consistent with other studies that
reported lower effectiveness of ARV in individuals over
50. These studies have attributed it to higher proportion
of late diagnosis in this age group [21,22], higher preva-
lence of comorbidity, and decreased immune response
with age [18]. This finding is particularly important be-
cause recent data from southern Brazil have indicated an
increase in new cases among individuals over 50 [23].
Another important finding is that shorter survival time
was independently associated with the exposure category
of IDU, which is consistent with the literature. A possible
explanation may be a higher prevalence of co-infection of
HIV and hepatitis B and C in this group [17,18,24]. The
authors of a study conducted in Sao Paulo argued that it
might be due to lower access to HAART and lower CD4+
counts at AIDS diagnosis [25].
The independent association between low schooling
and lower survival of AIDS patients may be explained by
the fact that disease perception is affected by level of
education; educated individuals are more likely to have
an early diagnosis and adhere to treatment [25]. If we take
schooling as a proxy measure for socioeconomic status,
our results are consistent with higher AIDS mortality in
the city districts with greater social inequality [26].
The study results indicated an association between low
CD4+ counts at AIDS diagnosis and lower survival,
which corroborates the findings of several other studies.
CD4+ count is a major biological marker of immune sta-
tus [27-29] and an indicator of late diagnosis and untimely
treatment. Currently international consensus recommen-
dations for treatment initiation are based on CD4+ counts,
viral loads and clinical data [30,31].
A recent population-based cohort study investigated
5,160 AIDS patients in four of the five Brazilian regions
from 2003 to 2010 and found that 53.4% of patients
started treatment with CD4+ counts lower than 200 cells/
mm3 [32], which is close to that seen in our study. It is
suggestive of late diagnosis, reinforcing the need to imple-
ment strategies for early diagnosis and treatment. More-
over, descriptive data from this same cohort has shown
that the groups of patients who benefit less from the intro-
duction of HAART still comprise a significant portion of
AIDS patients in Brazil.
It is important to bear in mind the study limitations
while interpreting the results. First, data comparisons
were made based on the availability of drug regimens at
different times rather than on the actual use of these
treatments. However, many authors has supported and
used this approach [2,18,33]. Survival analysis studies
often use last known contact date as the censoring date
for patients with unknown death information, which can
lead to overestimation of survival if a significant propor-
tion of patients with lower survival was lost to follow-up.
Another limitation was the use of different AIDS case def-
initions over time. The use of more sensitive case defini-
tions allowed to diagnose an increased number of cases at
a late period, which may have overestimated survival com-
pared to the number of patients diagnosed in the earlier
study periods. Despite these limitations, our results are
consistent with the literature and support ongoing im-
provement of AIDS control strategies.
Although factors affecting HAART effectiveness may
vary in different populations and backgrounds, our re-
sults were obtained under conditions that are in effect
comparable to those found in other low- and middle-
income countries. These countries have greatly ex-
panded access to ARV treatment in recent years [34],
which stresses the valuable contribution of the present
study.
Conclusions
This study emphasizes the impact of HAART introduc-
tion, lowering the mortality rates and increasing sur-
vival of AIDS patients. It indicated benefits with early
initiation of HAART, and identified groups of patients
that benefited less from new drug regimens. This find-
ing should be taken into consideration to improve AIDS
control programs. Our results also suggest that public
policies promoting health equity create an enabling en-
vironment helping AIDS control programs in develop-
ing countries to achieve their goals as effectively as in
developed countries.
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